Konakion Mm Paediatric Ampoules (Phytomenadione)

Phytomenadione serves as a co‑factor for the γ‑carboxylation of glutamic acid residues on clotting factors II, VII, IX and X in the liver. This enzymatic step enables the factors to bind calcium and become biologically active, thereby restoring normal coagulation.

The dose is determined by the prescribing clinician based on the patient’s age, weight, clinical condition and the indication. The product is administered by a healthcare professional via the appropriate route (intramuscular, intravenous or oral) according to the prescriber’s instructions.

Safety data for phytomenadione in pregnancy and lactation are limited. It should only be used when clearly indicated and prescribed by a qualified healthcare professional, who will weigh the potential benefits against any possible risks to the mother and infant.

Enquiries are submitted through the product page on gnhindia.com, where the required quantity is entered. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Konakion Mm Paediatric Ampoules contain phytomenadione, the natural form of vitamin K1, and are presented in a sterile ampoule suitable for parenteral use. Compared with synthetic analogues such as menadione (vitamin K3), phytomenadione has a more favorable safety profile and is the preferred agent for neonatal prophylaxis and anticoagulant reversal.

The ampoules should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any ampoule that appears discolored or compromised.

Administration is performed by a qualified healthcare professional. The ampoule can be given intramuscularly, intravenously, or orally, depending on the clinical situation and the prescriber’s order. Proper aseptic technique is required for parenteral routes.

Serious adverse reactions, although rare, include anaphylaxis, thrombosis and hemolysis. Immediate medical attention is required if signs of severe allergic reaction, unexpected clot formation, or sudden hemolytic symptoms occur after administration.

The product should be avoided in individuals with known hypersensitivity to phytomenadione or any excipients in the formulation. Caution is advised in patients with a history of severe allergic reactions, and it should only be used under medical supervision in newborns and other vulnerable populations.